CD47 and non-small cell lung carcinoma: Trials involving the CD47 antibody magrolimab include phase 1 PNOC025 (NCT05169944) for progressive brain tumors and Phase 2 (NCT04827576) for NSCLC and urothelial carcinoma (UC).